Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Study sponsor: Ascentage Pharma Group Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-06Estimated
Enrollment · participants490Estimated
Source updated2026-10-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.